TX-MAVENIR
11.7.2022 15:02:06 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced multiple Communications Service Providers (CSPs) are upgrading their Business Support System (BSS) with Mavenir’s Digital Enablement Platform (MDE) to offer new digital services that monetize 5G network investments.
MDE is a cloud-native, catalog-driven digital BSS that enables CSPs to easily create new 5G digital offerings or complete the 5G network transformation with charging and mediation functions and can also be used to design a digital marketplace experience, bundling cross-industry partner products and services into unified offerings. “With Mavenir’s MDE platform, CSPs can innovate fearlessly by rapidly introducing new services, and capture their customers’ interest, to become an integral part of their digital life,” said Sandeep Singh, GM Digital Enablement at Mavenir.
MDE can run as a comprehensive BSS or importantly, as a digital overlay with existing legacy BSS for minimal risk and disruption. BSS digital overlay systems can help CSPs to maximize returns in the 5G era. Analysys Mason forecasts, “The digital overlay approach can also reduce costs considerably, potentially saving CSPs up to 50% over 3-5 years when compared with traditional transformation approaches.1 ”
Recent deployment examples of Mavenir’s MDE include:
- A leading CSP in Japan for business-to-business (B2B) mobility services
CSP successfully launched its Mobility Bundle Services targeted toward business customers. The typical service includes a bundle of SIM+Handsets purchased in bulk (10s-1000s). The BSS provided a first-of-its-kind agile, co-development, automated CI/CD enabling quarterly updates including modules like Product Catalog, CRM, CPQ, Order Management, Provisioning, Inventory tracking, Offline Rating & Charging, Billing, Invoicing, Payments and Collections.
Mavenir’s digital BSS, deployed as overlay BSS, is the primary for managing B2B customer account lifecycle and connects back to the existing consumer BSS, to leverage capabilities for Individual SIM activation, Number Portability workflow, Resource Inventory management and Network Mediation.
Deployment is on CSP's private cloud over the Kubernetes-based Containers-as-a-Service (CaaS) and Platform as a service (PaaS) layer.
- Large MVNO in Germany transitioning to MNO deploying MDE converged charging system (CCS) & Charging Gateway Function (CGF) for 4G+5G Converged Charging
Transitioning to becoming an MNO with owned RAN, Core, IT, BSS, and Charging system. The CCS includes the 4G OCS enabling Voice, SMS, Data service rating, and charging on real-time Diameter interfaces by integrating with the EPC and IMS network elements. The same core CCS engine also includes 5G CHF, integrated with Mavenir 5GC (5G Core) NFs. The Charging Gateway Function (CGF), also part of the CCS solution, provides for a modern microservice-based network and billing mediation functionality. While the first set of services, including 5G FWA is expected to go live in 2022, the solution is designed to deliver charging for Voice, Messaging, Data (4G+5G eMBB) and IoT in truly agile CI/CD based updates over the next two years. Deployment is on CSP's private cloud over the Kubernetes-based CaaS and PaaS layer.
- Greenfield CSP in Guyana selects MDE for E2E BSS and Charging
Deploying end-to-end BSS and Charging for their 4G+5G Mobile and Fixed Wireless service rollout. The first phase of this multi-phase enables the CSP to launch Prepaid LTE Voice, Data, and SMS services in 2022, leveraging a 4G OCS (Online Charging System) solution for prepaid voice, data, and messaging charging. The second phase will introduce Postpaid services built on top of the BSS. The final phase includes the launch of the 5G eMBB service that will be deployed using MDE 5G CCS integrated with the other vendor's 5GC.
Supporting material:
Mavenir Digital Enablement (MDE) Solution Brief
MDE Introduction Video
MDE Composable BSS Video
Mavenir’s Charging Gateway Function Solution Brief
Mavenir’s Converged Charging Solution Brief
Mavenir’s Converge Charging System Video
Other MDE resources –
MDE Digital Marketplace Whitepaper
MDE solution For MVNOs & Digital Brands
MDE IoT Business Management Solution Brief
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
1 Analysys Mason/Mavenir White Paper “BSS digital overlay systems can help CSPs to maximize returns in the 5G era ” – June 2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005119/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom